{"allowContribute":false,"item":{"content":"\u003e 黃建霖 整理｜2026-07-26｜提供謝博士參考\n\n---\n\n## 一、背景：為什麼論文只收 8 例\n\n光田醫院實際執行脊髓損傷自體骨髓間質幹細胞治療已有數十例（參見「幹細胞個管(更).xlsx」），但本次 SCI 論文僅收錄 8 例胸椎 ASIA A 患者。原因如下：\n\n1. 再生醫療雙法架構下，只有登入國家管理系統（特管登錄）的案例才算合法合規\n2. 數十例中僅這 8 例有正式登入特管系統；其餘為醫病私下協議執行、未登入系統\n3. 學術發表只能使用合規案例的數據，私下執行者不具學術使用資格\n\n因此，8 例並非隨機抽樣，而是「光田全部合規案例的子集」。論文結論（62.5% A→B 改善率、\u003c18 月治療窗口 100% 轉換）基於這個特定子集，需在論文中清楚說明收案邏輯。\n\n---\n\n## 二、核心問題：特管免 IRB 數據的學術接受度\n\n這份論文面臨一個台灣再生醫療領域共同的學術發表障礙：\n\n- **臨床試驗**：必須經過 IRB（機構審查委員會）倫理審查 → 國際期刊普遍接受\n- **特管辦法／再生醫療法**：屬國家監管路徑，由衛福部審查治療計畫之安全性與合理性 → 不要求 IRB 審查\n- **本論文 8 例數據全部來自特管路徑 = 無 IRB 核准紀錄**\n\n**核心不確定性**：期刊審稿人是否接受「國家監管審查」等同於「IRB 倫理審查」？\n\n黃建霖觀點：敘明國家已開放此路徑即可，但坦承學界態度不明。\n\n---\n\n## 三、搜尋結果摘要\n\n經搜尋國際文獻與期刊政策：\n\n### ✅ 已確認\n- Cell Transplantation 曾刊登台灣細胞治療臨床論文（如 StemCyte MC001 脊髓損傷試驗），但該案為正規臨床試驗（有 IRB），非特管路徑\n- 台灣特管辦法下已有臨床數據發表於國際期刊，常見期刊包括 Journal of the Formosan Medical Association、Biomedical Journal 等，資料型態多為病例報告或回顧性分析\n- 日本再生医療等安全性確保法（ASRM，台灣特管的設計原型）已有論文發表先例\n\n### ❌ 未找到\n- 明確標註「無 IRB、僅依國家監管路徑」且被國際期刊接受的完全對應前例\n\n→ **這不表示會被拒絕，只表示我們是這個議題的開路先鋒。**\n\n---\n\n## 四、三層防禦策略\n\n### 第一層：倫理論述（論文內，Ethics Statement）\n\n建議不要只寫「經特管核准」一句話帶過，而是在 Ethics Statement 中建立完整論證：\n\n\u003e This study analyzed clinical data from patients treated under Taiwan's Special Regulation for Cell Therapy (now incorporated into the Regenerative Medicine Act of 2026). This national regulatory pathway, modeled after Japan's Act on Safety of Regenerative Medicine (ASRM), requires Ministry of Health and Welfare review of treatment plans for safety and rationale prior to implementation. The regulatory review serves as the functional equivalent of institutional review board (IRB) oversight in ensuring patient safety and ethical compliance. All patients provided written informed consent prior to treatment.\n\n**關鍵修辭策略**：\n- 使用「functional equivalent of IRB oversight」建立對等關係\n- 引用日本 ASRM 作為制度原型，增加國際審稿人的理解度\n- 強調「所有患者簽署知情同意書」，這是 IRB 的核心功能之一\n\n---\n\n### 第二層：Cover Letter 先發制人\n\n投稿時在 Cover Letter 中加入一段，主動解決審稿人的潛在疑問：\n\n\u003e We wish to draw the Editor's attention to the data provenance of this manuscript. The clinical cases reported herein derive from a nationally regulated cell therapy program in Taiwan, rather than a conventional prospective clinical trial. Taiwan's regulatory framework for cell therapy was explicitly designed after Japan's Act on Safety of Regenerative Medicine (ASRM). The Ministry of Health and Welfare reviews each treatment plan prior to approval, and we submit that this national-level regulatory oversight provides equivalent ethical protection to institutional IRB review, consistent with the Declaration of Helsinki's provision for alternative ethical review mechanisms recognized by national authorities.\n\n---\n\n### 第三層：期刊策略\n\n| 順序 | 期刊 | 理由 |\n|:---:|------|------|\n| 首選 | **Cell Transplantation** (IF 3.7) | 曾刊登台灣細胞治療論文，translational journal，對 real-world clinical data 接受度較高 |\n| 備案A | **Stem Cells International** | Open access（Hindawi/Wiley），對非傳統試驗設計較開放 |\n| 備案B | **Frontiers in Neurology** | Open access，明確歡迎 real-world evidence / observational studies，倫理政策較彈性 |\n\n---\n\n### 補充行動：Pre-submission Inquiry\n\n最務實的做法是在正式投稿前，先寫信詢問 Cell Transplantation 的編輯部：\n\n\u003e Dear Editor,\n\u003e\n\u003e We have prepared a manuscript reporting a case series of 8 patients with thoracic complete spinal cord injury (ASIA A) treated with autologous bone marrow-derived mesenchymal stem cells. The treatments were conducted under Taiwan's national cell therapy regulatory pathway (Special Regulation for Cell Therapy, now part of the Regenerative Medicine Act), which mandates Ministry of Health and Welfare review but does not require separate institutional IRB approval—the national regulatory body serves as the ethical oversight mechanism, modeled after Japan's ASRM.\n\u003e\n\u003e We would appreciate your guidance on whether Cell Transplantation considers clinical data generated under such a nationally-regulated pathway admissible for publication, or if additional ethical review documentation would be required.\n\u003e\n\u003e Thank you for your consideration.\n\n---\n\n## 五、建議行動順序\n\n1. 將「第一層 Ethics Statement」英文段落納入論文修改\n2. 若決定先詢問編輯部，使用「Pre-submission Inquiry」草稿發信\n3. 視回覆結果決定首選期刊（Cell Transplantation 或直接走備案）\n4. Cover Letter 段落留待正式投稿時使用\n5. **無論選哪本期刊，論文內 Ethics Statement 的完整論述都是必要功課——不要只寫一句話**","createdAt":1785037696146,"deletedAt":null,"id":"b6dce13f9931c5a98f155ca1","isNew":false,"isPublic":true,"itemType":"NOTE","name":"光田SCI論文 — IRB與特管數據發表策略建議（謝博士用）","parents":{"706be38aac6ae5202055663a":1785037696146},"preParentID":null,"updatedAt":1785037818308,"updatedBy":{"userId":"6a348122019812653adbab","userName":"泰倫斯"},"version":3},"ownerName":"J-Lin","subtree":[{"content":"\u003e 黃建霖 整理｜2026-07-26｜提供謝博士參考\n\n---\n\n## 一、背景：為什麼論文只收 8 例\n\n光田醫院實際執行脊髓損傷自體骨髓間質幹細胞治療已有數十例（參見「幹細胞個管(更).xlsx」），但本次 SCI 論文僅收錄 8 例胸椎 ASIA A 患者。原因如下：\n\n1. 再生醫療雙法架構下，只有登入國家管理系統（特管登錄）的案例才算合法合規\n2. 數十例中僅這 8 例有正式登入特管系統；其餘為醫病私下協議執行、未登入系統\n3. 學術發表只能使用合規案例的數據，私下執行者不具學術使用資格\n\n因此，8 例並非隨機抽樣，而是「光田全部合規案例的子集」。論文結論（62.5% A→B 改善率、\u003c18 月治療窗口 100% 轉換）基於這個特定子集，需在論文中清楚說明收案邏輯。\n\n---\n\n## 二、核心問題：特管免 IRB 數據的學術接受度\n\n這份論文面臨一個台灣再生醫療領域共同的學術發表障礙：\n\n- **臨床試驗**：必須經過 IRB（機構審查委員會）倫理審查 → 國際期刊普遍接受\n- **特管辦法／再生醫療法**：屬國家監管路徑，由衛福部審查治療計畫之安全性與合理性 → 不要求 IRB 審查\n- **本論文 8 例數據全部來自特管路徑 = 無 IRB 核准紀錄**\n\n**核心不確定性**：期刊審稿人是否接受「國家監管審查」等同於「IRB 倫理審查」？\n\n黃建霖觀點：敘明國家已開放此路徑即可，但坦承學界態度不明。\n\n---\n\n## 三、搜尋結果摘要\n\n經搜尋國際文獻與期刊政策：\n\n### ✅ 已確認\n- Cell Transplantation 曾刊登台灣細胞治療臨床論文（如 StemCyte MC001 脊髓損傷試驗），但該案為正規臨床試驗（有 IRB），非特管路徑\n- 台灣特管辦法下已有臨床數據發表於國際期刊，常見期刊包括 Journal of the Formosan Medical Association、Biomedical Journal 等，資料型態多為病例報告或回顧性分析\n- 日本再生医療等安全性確保法（ASRM，台灣特管的設計原型）已有論文發表先例\n\n### ❌ 未找到\n- 明確標註「無 IRB、僅依國家監管路徑」且被國際期刊接受的完全對應前例\n\n→ **這不表示會被拒絕，只表示我們是這個議題的開路先鋒。**\n\n---\n\n## 四、三層防禦策略\n\n### 第一層：倫理論述（論文內，Ethics Statement）\n\n建議不要只寫「經特管核准」一句話帶過，而是在 Ethics Statement 中建立完整論證：\n\n\u003e This study analyzed clinical data from patients treated under Taiwan's Special Regulation for Cell Therapy (now incorporated into the Regenerative Medicine Act of 2026). This national regulatory pathway, modeled after Japan's Act on Safety of Regenerative Medicine (ASRM), requires Ministry of Health and Welfare review of treatment plans for safety and rationale prior to implementation. The regulatory review serves as the functional equivalent of institutional review board (IRB) oversight in ensuring patient safety and ethical compliance. All patients provided written informed consent prior to treatment.\n\n**關鍵修辭策略**：\n- 使用「functional equivalent of IRB oversight」建立對等關係\n- 引用日本 ASRM 作為制度原型，增加國際審稿人的理解度\n- 強調「所有患者簽署知情同意書」，這是 IRB 的核心功能之一\n\n---\n\n### 第二層：Cover Letter 先發制人\n\n投稿時在 Cover Letter 中加入一段，主動解決審稿人的潛在疑問：\n\n\u003e We wish to draw the Editor's attention to the data provenance of this manuscript. The clinical cases reported herein derive from a nationally regulated cell therapy program in Taiwan, rather than a conventional prospective clinical trial. Taiwan's regulatory framework for cell therapy was explicitly designed after Japan's Act on Safety of Regenerative Medicine (ASRM). The Ministry of Health and Welfare reviews each treatment plan prior to approval, and we submit that this national-level regulatory oversight provides equivalent ethical protection to institutional IRB review, consistent with the Declaration of Helsinki's provision for alternative ethical review mechanisms recognized by national authorities.\n\n---\n\n### 第三層：期刊策略\n\n| 順序 | 期刊 | 理由 |\n|:---:|------|------|\n| 首選 | **Cell Transplantation** (IF 3.7) | 曾刊登台灣細胞治療論文，translational journal，對 real-world clinical data 接受度較高 |\n| 備案A | **Stem Cells International** | Open access（Hindawi/Wiley），對非傳統試驗設計較開放 |\n| 備案B | **Frontiers in Neurology** | Open access，明確歡迎 real-world evidence / observational studies，倫理政策較彈性 |\n\n---\n\n### 補充行動：Pre-submission Inquiry\n\n最務實的做法是在正式投稿前，先寫信詢問 Cell Transplantation 的編輯部：\n\n\u003e Dear Editor,\n\u003e\n\u003e We have prepared a manuscript reporting a case series of 8 patients with thoracic complete spinal cord injury (ASIA A) treated with autologous bone marrow-derived mesenchymal stem cells. The treatments were conducted under Taiwan's national cell therapy regulatory pathway (Special Regulation for Cell Therapy, now part of the Regenerative Medicine Act), which mandates Ministry of Health and Welfare review but does not require separate institutional IRB approval—the national regulatory body serves as the ethical oversight mechanism, modeled after Japan's ASRM.\n\u003e\n\u003e We would appreciate your guidance on whether Cell Transplantation considers clinical data generated under such a nationally-regulated pathway admissible for publication, or if additional ethical review documentation would be required.\n\u003e\n\u003e Thank you for your consideration.\n\n---\n\n## 五、建議行動順序\n\n1. 將「第一層 Ethics Statement」英文段落納入論文修改\n2. 若決定先詢問編輯部，使用「Pre-submission Inquiry」草稿發信\n3. 視回覆結果決定首選期刊（Cell Transplantation 或直接走備案）\n4. Cover Letter 段落留待正式投稿時使用\n5. **無論選哪本期刊，論文內 Ethics Statement 的完整論述都是必要功課——不要只寫一句話**","createdAt":1785037696146,"deletedAt":null,"id":"b6dce13f9931c5a98f155ca1","isNew":false,"isPublic":true,"itemType":"NOTE","name":"光田SCI論文 — IRB與特管數據發表策略建議（謝博士用）","parents":{"706be38aac6ae5202055663a":1785037696146},"preParentID":null,"updatedAt":1785037818308,"updatedBy":{"userId":"6a348122019812653adbab","userName":"泰倫斯"},"version":3}]}